Research location
Lauderhill
Florida, United States
Advertisement
Research activity in Lauderhill
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 101 trials and 102 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lauderhill
101 linked trials · page 1 of 3Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 2026-07-23 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation
RECRUITING
A Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877 · 2026-01-20 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 · 2024-10-02 · 1 site observation
RECRUITING
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)NCT06605105 · 2025-07-18 · 1 site observation
ENROLLING_BY_INVITATION
Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityNCT06585462 · 2024-09-09 · 1 site observation
COMPLETED
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.NCT06429722 · 2024-05-13 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT06254612 · 2024-03-25 · 1 site observation
COMPLETED
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · 2024-03-18 · 1 site observation
COMPLETED
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · 2024-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 · 2023-12-20 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408 · 2023-03-02 · 1 site observation
COMPLETED
ANC-501 in the Treatment of Adults With Major Depressive DisorderNCT05439603 · 2022-09-19 · 1 site observation
COMPLETED
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05304767 · 2022-03-07 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation
COMPLETED
Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseNCT04994483 · 2021-11-03 · 1 site observation
COMPLETED
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's DiseaseNCT04520412 · 2020-10-27 · 1 site observation
SUSPENDED
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT04479852 · 2020-09-30 · 1 site observation
COMPLETED
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderNCT04512066 · 2020-09-08 · 1 site observation
COMPLETED
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 · 2020-08-18 · 1 site observation
TERMINATED
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive DisorderNCT04353921 · 2020-06-30 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)NCT04442490 · 2020-05-12 · 1 site observation
COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderNCT04285515 · 2020-02-27 · 1 site observation
COMPLETED
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · 2020-01-23 · 1 site observation
COMPLETED
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230 · 2020-01-03 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaNCT04158687 · 2019-11-26 · 1 site observation
COMPLETED
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367 · 2019-08-06 · 1 site observation
TERMINATED
Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022 · 2019-07-08 · 1 site observation
COMPLETED
A Trial of AXS-05 in Patients With Major Depressive DisorderNCT04019704 · 2019-06-20 · 1 site observation
COMPLETED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®NCT03892889 · 2019-04-29 · 1 site observation
TERMINATED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · 2019-04-17 · 1 site observation
COMPLETED
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsNCT03669640 · 2018-12-04 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175 · 2018-11-19 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)NCT03745820 · 2018-11-15 · 1 site observation
COMPLETED
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeNCT03692910 · 2018-08-23 · 1 site observation
COMPLETED
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)NCT03668600 · 2018-08-23 · 1 site observation
TERMINATED
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)NCT03610048 · 2018-08-09 · 1 site observation
TERMINATED
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)NCT03614156 · 2018-08-02 · 1 site observation
TERMINATED
ERG Components in Schizophrenia and Bipolar Disorder Type INCT03788811 · 2018-07-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Rapastinel as Monotherapy in Patients With MDDNCT03560518 · 2018-06-15 · 1 site observation
TERMINATED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaNCT03503318 · 2018-04-27 · 1 site observation
COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT03393520 · 2017-10-13 · 2 site observations
COMPLETED
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyNCT03227224 · 2017-08-16 · 1 site observation
COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15 · 1 site observation
COMPLETED
BTRX-246040 Administered Once Daily to Patients With Major Depressive DisorderNCT03193398 · 2017-06-12 · 1 site observation
COMPLETED
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)NCT03188185 · 2017-06-12 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.